This is unpublished

Brian G.
Till
M.D.

he, him, his
Physician & Research Faculty
Pinned
Academic
Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center
Associate Professor, Division of Medical Oncology, University of Washington
Sites of Practice
Seattle Cancer Care Alliance

Photo: SCCA

Education, Training, Board Certifications 

  • M.D., University of Chicago 
  • Residency, Hospital of the University of Pennsylvania 
  • Fellowship in Medical Oncology, UW/Fred Hutch 
  • Medical Oncology, American Board of Internal Medicine 

Clinical Expertise 

  • Immunotherapy 
  • CAR T-cell therapy 
  • Hematopoietic stem cell transplantation 
  • Lymphoma

Affiliations

Publications

Research and/or clinical interests 

Dr. Brian Till develops new treatments for lymphoma by genetically engineering a patient's own T cells so they can more effectively attack cancer. T cells target and kill cancer cells by binding to specific proteins on the tumor cells with molecules called T-cell receptors. Dr. Till's research involves making synthetic receptors known as chimeric antigen receptors, or CARs, that home in on lymphoma cells. He led the first published trial testing CAR T cells as a treatment for lymphoma patients. Dr. Till continues to carry out a variety of immunological, genetic and gene-expression studies in the clinic to understand why CAR T-cell therapies work for some patients and fail for others. This research will help improve the next iterations of this experimental therapy.